The FDA has officially approved Eli Lilly’s donanemab, marking a major advancement in Alzheimer’s treatment. This monoclonal antibody therapy works by targeting and clearing amyloid plaques, a key characteristic of Alzheimer’s disease. With this approval, Lilly strengthens its foothold in the competitive market, providing new hope for patients.
Donanemab vs. Lecanemab: A...
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek